Clinical trials: Sclerosis
Pediatric Multiple Sclerosis
ATOMIC (Active Teens With MultIple sClerosis) Teens: A Feasibility Study
Taking part in recommended levels of physical activity in youth with MS may have an important and positive impact on disease symptoms, long-term disability and health outcomes. Unfortunately, youth with MS are highly inactive.
- Trial name
- NCT03137602
- Testing
- ATOMIC mobile app
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- The Hospital for Sick Children
Spinal Cord Injuries, Cerebral Palsy
LEAP a New Overground Body Weight Support Robot: Usability Trial
People with central nervous system disorders such as spinal cord injury, stroke, cerebral palsy, Parkinson's disease, multiple sclerosis, etc… often have impaired lower extremity function that limits activities of daily life and…
- Conditions
- Spinal Cord Injuries, Cerebral Palsy, Parkinson Disease, Multiple Sclerosis
- Trial name
- LEAP (NCT03458169)
- Testing
- Therapist LEAP session feedback, Participant LEAP session feedback, LEAP risk control validation
- Where
- Switzerland
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Clinique Romande de Readaptation
Multiple Sclerosis
Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients
Serum neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) measured by single molecule array (SIMOA) are novel biomarkers of multiple sclerosis patients (MS) activity and progression.
- Trial name
- Nf-Ella Loca (NCT05352971)
- Testing
- Biomarker quantification
- Where
- 10 sites in France
- Volunteers
- 664 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Dementia, Movement Disorders
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.
The goal of this clinical study is to compare the current standard-of-care PET/CT scanner with the new NeuroEXPLORER PET/CT, with the aim of demonstrating the added diagnostic value of the new scanner.
- Conditions
- Dementia, Movement Disorders, ALS - Amyotrophic Lateral Sclerosis, Epilepsy
- Trial name
- NCT07595666
- Testing
- Standard-of-care PET/CT, NeuroEXPLORER
- Where
- Belgium
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- prof. dr. Koen Van Laere
Multiple Sclerosis, Exposure During Pregnancy
Biogen Multiple Sclerosis Pregnancy Exposure Registry
The primary objective of the study is to prospectively evaluate pregnancy outcomes in women with multiple sclerosis who were exposed to a Registry-specified Biogen Multiple Sclerosis product during the eligibility window for that…
- Trial name
- NCT01911767
- Testing
- Dimethyl fumarate, Peginterferon beta-1a
- Where
- 15 sites in United States, Australia and 8 more
- Volunteers
- 408 people
- Sponsor
- Biogen
Multiple Sclerosis, Clinically Isolated Syndrome
AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS
The definition of the most 'at-risk' population within highly susceptible groups would provide an opportunity for preemptive therapeutics.
- Trial name
- ARMS (NCT00617383)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Pain, Traumatic Brain Injury
The NRC Dataset. Developing a Minimum Dataset for Multidisciplinary Rehabilitation: a Modified E-Delphi Study
Several rehabilitation datasets are presently in use for specific patient groups in England. The 'National Clinical Audit of Specialist Rehabilitation for patients with complex needs following major injury' (NCASRI) evaluated…
- Conditions
- Pain, Traumatic Brain Injury, Major Trauma, Multiple Sclerosis
- Trial name
- NCT06726135
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ThomasCorbett
Multiple Sclerosis
Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS Patients (COPP-MS)
Multiple Sclerosis (MS) is most prevalent among women of childbearing age. The post-partum (PP) period is a critical phase in MS patients, during which a recrudescence of disease activity is expected.
- Trial name
- COPP-MS (NCT03917589)
- Where
- 5 sites in France
- Volunteers
- 350 people
- Sponsor
- Rennes University Hospital
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is two to three years.
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Nervous System Diseases, Spinal Cord Diseases
- Trial name
- ALS-LTMV (NCT05744310)
- Testing
- Long term mechanical ventilation support, No long term mechanical ventilation support
- Where
- 9 sites in Norway
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Multiple Sclerosis
Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)
The treatment of multiple sclerosis was evolving in light of specific drug therapies to treat the disease, refinements and acceptance of imaging with MRI to diagnose and monitor the disease process, and progress in understanding…
- Trial name
- NCT00439257
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- US Department of Veterans Affairs
Diffusion Limitation of Pulmonary Gas Exchange in Systemic Sclerosis
Mechanisms of Pulmonary Diffusion Limitation in Systemic Sclerosis
This study was designed to test the hypothesis that, irrespective of the degree of interstiaI lung disease and/or pulmonary arterial hypertension, the combined measurement of lung diffusing capacity for nitric oxide and carbon…
- Trial name
- DL-SSc (NCT03601520)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Multiple Sclerosis, Relapsing-Remitting
Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation
The underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as Multiple Sclerosis (MS), are incompletely understood.
- Trial name
- BIO-MS (NCT06195800)
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Ehlers-Danlos Syndrome, Multiple Sclerosis
Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)
The investigators propose that evidence of chronic cerebrospinal venous insufficiency (CCSVI) may be evident in the vasculature of the fundus.
- Trial name
- NCT01356134
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Genetic Disease Investigators
Multiple Sclerosis
Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
The primary objective of the study is to evaluate the safety of natalizumab use in the pediatric multiple sclerosis (MS) population.
- Trial name
- NCT02137109
- Testing
- natalizumab
- Volunteers
- 400 people
- Sponsor
- Biogen
Multiple Sclerosis
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants who Have Participated in Cladribine Clinical Trials
- Trial name
- PREMIERE (NCT01013350)
- Where
- United States
- Volunteers
- 1,161 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)
The aim of this retrospective study is to review and describe safety, tolerability and efficacy of Rebif® (subcutaneous interferon [IFN]-beta-1a) in children and adolescents, using information already recorded in medical records.
- Trial name
- REPLAY (NCT01207648)
- Testing
- Rebif®
- Where
- 18 sites in United States, Argentina and 6 more
- Volunteers
- 307 people
- Sponsor
- EMD Serono
Multiple Sclerosis (MS)
Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis
This single-center interventional study quasi-randomly allocated patients to a guided imagery or control intervention (positive journaling). Data were analyzed with treatment allocation masked.
- Trial name
- HLGI (NCT03177655)
- Testing
- Guided Imagery, Journaling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
Tuberous Sclerosis Complex
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.
- Trial name
- NCT05495425
- Testing
- NPC-12Y gel
- Where
- 5 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Nobelpharma
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
The main purpose of this study is to evaluate the pharmacokinetics (PK) of ocrelizumab administered subcutaneously (SC) in children and adolescents aged 10 to <18 years with RRMS.
- Trial name
- Operetta III (NCT07503340)
- Testing
- Ocrelizumab co-formulated with rHuPH20
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche